Recent Advances in Nuclear Medicine/Radiopharmaceuticals

The chronic diseases such as heart diseases, cancer, chronic lung diseases, stroke, Alzheimer’s disease, and chronic kidney disease and other neurological disorders are growing at a rapid rate across the globe. These chronic diseases are the leading cause of deaths. According to the recent statistics of World Health Organization for the year 2019, states that chronic disease contributes approximately 60% of all deaths and 43% of the global burden of disease. It is also expected that by 2020 the incidences of deaths will rise approximately to 73% and the global burden of disease is expected to grow by 60%.

DOWNLOAD SAMPLE PDF COPY OF THIS STUDY

According to the World Health Organization in 2018, cancer was the second leading cause of death across the globe, and is responsible for an estimated 9.6 million deaths in 2018. Furthermore, the American Cancer Society estimated that in 2018, approximately 1,735,350 new cancer cases were diagnosed.

SPECT Nuclear Medicine VS PET Nuclear Medicine

A single-photon emission computerized tomography (SPECT) scan creates 3D images of the internal organs and helps the healthcare professionals in analyzing the function of some of internal organs. A SPECT scan uses nuclear medicine and helps in diagnosing and tracking the progression of heart disease, such as blocked coronary arteries. SPECT agents are also available for diagnosing neurological conditions such as Parkinson's. The SPECT nuclear medicine market is driving due to the growing incidence and prevalence of target health conditions, and increasing number of SPECT procedures. However, short half-life of radiopharmaceuticals may hamper the growth of the global SPECT nuclear medicine industry.

Whereas, PET nuclear medicine procedure is used to determine the metabolic activity of the cells in the body. Positron emission tomography (PET) scan, an imaging test helps in understanding the tissues and organs functioning in the patient. It helps in diagnosing, evaluating and treating a variety of diseases. The PET nuclear medicine industry is driving due to the growing incidence and prevalence of target health conditions, and increasing number of PET procedures.

Profiling Companies:

Cardinal Health, IBA Worldwide, Curium, GENERAL ELECTRIC, Bayer AG, Positron Corporation, NTP Radioisotopes SOC Ltd., Bracco, Lantheus Medical Imaging Inc., Advanced Accelerator Applications.